Synapse - Works

Results (2639)

Whimsical (Waldenstrom's Macroglobulinemia Study Involving CArt-wheeL): A global patient-derived data registry capturing treatment, quality of life and COVID-19 data

Meeting Abstract

Tohidi-Esfahani, I.; Warden, A.; Malunis, E.; deNardis, P. L.; Haurat, J.; Black, M.; Opat, S.; D'Sa, S.; Kersten, M. J.; Spearing, R.; more...
Blood (2020)

Fulltext@MSK | Save

Evolving treatment patterns in chronic lymphocytic leukemia among experts and community practitioners: Analysis of an online decision support tool

Meeting Abstract

Topping, R. P.; Rosenthal, K.; Awan, F. T.; Brown, J. R.; Lamanna, N.; Sharman, J. P.; Quill, T. A.; Zelenetz, A. D.
Blood (2020)

Fulltext@MSK | Save

Venetoclax re-treatment of chronic lymphocytic leukemia (CLL) patients after a previous venetoclax-based regimen

Meeting Abstract

Thompson, M. C.; Allan, J. N.; Sail, K.; Manzoor, B. S.; Pu, J. J.; Barr, P. M.; Coombs, C. C.; Schuster, S. J.; Skarbnik, A.; Rhodes, J. M.; more...
Blood (2020)

Fulltext@MSK | Save

Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III/IV classical hodgkin lymphoma: 5-year update of the ECHELON-1 study

Meeting Abstract

Straus, D. J.; Dlugosz-Danecka, M.; Connors, J. M.; Illés, A.; Picardi, M.; Lech-Marańda, E.; Feldman, T.; Smolewski, P.; Savage, K. J.; Bartlett, N. L.; more...
Blood (2020)

Fulltext@MSK | Save

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory diffuse large B-cell lymphoma: Updated results of a phase Ib/II randomized study and preliminary results of a single-arm extension

Meeting Abstract

Sehn, L. H.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S. E.; Flowers, C.; Kim, T. M.; McMillan, A.; Ozcan, M.; Safar, V.; more...
Blood (2020)

Fulltext@MSK | Save

Nivolumab combined with brentuximab vedotin for relapsed/refractory mediastinal gray zone lymphoma: Primary efficacy and safety analysis of the phase 2 CheckMate 436 study

Meeting Abstract

Santoro, A.; Moskowitz, A. J.; Ferrari, S.; Carlo-Stella, C.; Fanale, M. A.; Francis, S.; Sacchi, M.; Savage, K. J.
Blood (2020)

Fulltext@MSK | Save

Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL)

Meeting Abstract

Ruan, J.; Moskowitz, A. J.; Mehta-Shah, N.; Sokol, L.; Chen, Z.; Rahim, R.; Song, W.; Van Besien, K.; Horwitz, S. M.; Rutherford, S. C.; more...
Blood (2020)

Fulltext@MSK | Save

Favorable outcomes among patients with T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era

Meeting Abstract

Robin, E. T.; Drill, E.; Batlevi, C. L.; Caron, P.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Intlekofer, A. M.; Joffe, E.; more...
Blood (2020)

Fulltext@MSK | Save

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 primo trial: Dose optimization efficacy update and expansion phase initial results

Meeting Abstract

Pro, B.; Brammer, J. E.; Casulo, C.; Jacobsen, E.; Mead, M.; Mehta-Shah, N.; Zain, J. M.; Zinzani, P. L.; Lustgarten, S.; Youssoufian, H.; more...
Blood (2020)

Fulltext@MSK | Save

Costs of postinfusion monitoring by site of care for patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who received third-line or later treatment with lisocabtagene maraleucel (liso-cel) in the TRANSCEND NHL 001 and OUTREACH trials

Meeting Abstract

Palomba, M. L.; Jun, M. P.; Garcia, J.; Lymp, J.; McGarvey, N.; Gitlin, M.; Pelletier, C.; Nguyen, A.
Blood (2020)

Fulltext@MSK | Save